Analystreport

Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Robert W. Baird from $39.00 to $41.00. They now have an "outperform" rating on the stock.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report